Abstract Accurate delineation of clinical target volume (CTV) of nasopharyngeal carcinoma is of significance to prevent local recurrence and improve the survival rate of patients. When intensity-modulated radiotherapy (IMRT) was first introduced, CTV was delineated based on two-dimensional radiotherapy experience. The local recurrence-free survival is high, but the adverse reactions induced by radiotherapy are severe and the patients’ quality of life is poor. How to reduce CTV to alleviate acute and late radiotherapy-induced adverse reactions without deteriorating therapeutic effect has currently become a research hotspot. Despite the 2010 Chinese Nasopharyngeal Carcinoma IMRT Target and Dose Design Guideline Expert Consensus and the International Guideline for the Delineation of the CTV for Nasopharyngeal Carcinoma as references, the optimal individualized and standardized delineation of CTV remains controversial. This review summarizes the progress on the delineation of CTV of primary tumour of nasopharyngeal carcinoma, aiming to provide practical reference for clinicians.
Corresponding Authors:
Bai Yongrui, Email:baiyongruiz@163.com
Cite this article:
Lin Lin,Bai Yongrui. Progress on delineation of clinical target volume of primary tumour of nasopharyngeal carcinoma[J]. Chinese Journal of Radiation Oncology, 2022, 31(4): 383-388.
Lin Lin,Bai Yongrui. Progress on delineation of clinical target volume of primary tumour of nasopharyngeal carcinoma[J]. Chinese Journal of Radiation Oncology, 2022, 31(4): 383-388.
[1] Chen YP, Ismaila N, Chua M, et al. Chemotherapy in combination with radiotherapy for definitive-intent treatment of stage Ⅱ-IVA nasopharyngeal carcinoma:CSCO and ASCO guideline[J]. J Clin Oncol, 2021, 39(7):840-859. DOI:10.1200/JCO.20.03237. [2] Chen YP, Chan ATC, Le QT, et al. Nasopharyngeal carcinoma[J]. Lancet, 2019, 394(10192):64-80. DOI:10.1016/s0140-6736(19)30956-0. [3] Lee AW, Poon YF, Foo W, et al. Retrospective analysis of 5037 patients with nasopharyngeal carcinoma treated during 1976-1985:overall survival and patterns of failure[J]. Int J Radiat Oncol Biol Phys, 1992, 23(2):261-270. DOI:10.1016/0360-3016(92)90740-9. [4] Lee AW, Sze WM, Au JS, et al. Treatment results for nasopharyngeal carcinoma in the modern era:the Hong Kong experience[J]. Int J Radiat Oncol Biol Phys, 2005, 61(4):1107-1116. DOI:10.1016/j.ijrobp.2004.07.702. [5] Mao YP, Tang LL, Chen L, et al. Prognostic factors and failure patterns in non-metastatic nasopharyngeal carcinoma after intensity-modulated radiotherapy[J]. Chin J Cancer, 2016, 35(1):103. DOI:10.1186/s40880-016-0167-2. [6] Zhang B, Mo Z, Du W, et al. Intensity-modulated radiation therapy versus 2D-RT or 3D-CRT for the treatment of nasopharyngeal carcinoma:A systematic review and meta-analysis[J]. Oral Oncol, 2015, 51(11):1041-1046. DOI:10.1016/j.oraloncology.2015.08.005 [7] Lee AW, Ng WT, Pan JJ, et al. International guideline for the delineation of the clinical target volumes (CTV) for nasopharyngeal carcinoma[J]. Radiother Oncol, 2018, 126(1):25-36. DOI:10.1016/j.radonc.2017.10.032. [8] Lee AW, Ng WT, Pan JJ, et al. International guideline on dose prioritization and acceptance criteria in radiation therapy planning for nasopharyngeal carcinoma[J]. Int J Radiat Oncol Biol Phys, 2019, 105(3):567-580. DOI:10.1016/j.ijrobp.2019.06.2540. [9] Zhang S, Yang S, Xu P, et al. Variations of clinical target volume delineation for primary site of nasopharyngeal cancer among five centers in china[J]. Front Oncol, 2020, 10:1572. DOI:10.3389/fonc.2020.01572. [10] Sultanem K, Shu HK, Xia P, et al. Three-dimensional intensity-modulated radiotherapy in the treatment of nasopharyngeal carcinoma:the University of California-San Francisco experience[J]. Int J Radiat Oncol Biol Phys, 2000, 48(3):711-722. DOI:10.1016/s0360-3016(00)00702-1 [11] Lee N, Xia P, Quivey JM, et al. Intensity-modulated radiotherapy in the treatment of nasopharyngeal carcinoma:an update of the UCSF experience[J]. Int J Radiat Oncol Biol Phys, 2002, 53(1):12-22. DOI:10.1016/s0360-3016(02)02724-4. [12] Lee N, Harris J, Garden AS, et al. Intensity-modulated radiation therapy with or without chemotherapy for nasopharyngeal carcinoma:radiation therapy oncology group phase Ⅱ trial 0225[J]. J Clin Oncol, 2009, 27(22):3684-3690. DOI:10.1200/JCO.2008.19.9109. [13] 林少俊, 潘建基, 郭巧娟. 鼻咽癌临床靶区定义[J]. 中国癌症杂志, 2011, 12(12):913-919. DOI:10.3969/j.issn.1007-3969.2011.12.003. Lin SJ, Pan JJ, Guo QJ. Definition of clinical target volume (CTV) for nasopharyngeal carcinoma[J]. China Oncology,2011,12(12):913-919. DOI:10.3969/j.issn.1007-3969.2011.12.003. [14] Lee NY, Zhang Q, Pfister DG, et al. Addition of bevacizumab to standard chemoradiation for locoregionally advanced nasopharyngeal carcinoma (RTOG 0615):a phase 2 multi-institutional trial[J]. Lancet Oncol, 2012, 13(2):172-180. DOI:10.1016/S1470-2045(11)70303-5. [15] 赵充, 卢泰祥, 韩非, 等. 139例鼻咽癌调强放疗的临床研究[J]. 中华放射肿瘤学杂志, 2006, 15(1):1-6. DOI:10.3760/j.issn:1004-4221.2006.01.001. Zhao C, Lu TX, Han F, et al. Clinical study of 139 nasopharyngeal carcinoma patients for intensity modulated radiation therapy[J]. Chin J Radiat Oncol, 2006, 15(1):1-6. DOI:10.3760/j.issn:1004-4221.2006.01.001. [16] Lin S, Pan J, Han L, et al. Nasopharyngeal carcinoma treated with reduced-volume intensity-modulated radiation therapy:report on the 3-year outcome of a prospective series[J]. Int J Radiat Oncol Biol Phys, 2009, 75(4):1071-1078. DOI:10.1016/j.ijrobp.2008.12.015. [17] 易俊林, 高黎, 徐国镇, 等. 147例鼻咽癌调强放疗结果分析[J]. 中华放射肿瘤学杂志, 2008, 17(5):329-334. DOI:10.3321/j.issn:1004-4221.2008.05.001. Yi JL, Gao L, Xu GZ, et al. Treatment results of intensity-modulated radiotherapy for nasopharyngeal carcinoma:an analysis of 147 patients[J]. Chin J Radiat Oncol, 2008, 17(5):329-334. DOI:10.3321/j.issn:1004-4221.2008.05.001. [18] Lin S, Lu JJ, Han L, et al. Sequential chemotherapy and intensity-modulated radiation therapy in the management of locoregionally advanced nasopharyngeal carcinoma:experience of 370 consecutive cases[J]. BMC Cancer, 2010, 10:39. DOI:10.1186/1471-2407-10-39. [19] Lin S, Pan J, Han L, et al. Update report of nasopharyngeal carcinoma treated with reduced-volume intensity-modulated radiation therapy and hypothesis of the optimal margin[J]. Radiother Oncol, 2014, 110(3):385-389. DOI:10.1016/j.radonc.2014.01.011. [20] 中国鼻咽癌临床分期工作委员会. 2010鼻咽癌调强放疗靶区及剂量设计指引专家共识[J]. 中华放射肿瘤学杂志, 2011, 20(4):267-269. DOI:10.3760/cma.j.issn.1004-4221.2011.04.001. China NPC clinical staging Committee.2010 Nasopharyngeal carcinoma intensity modulated radiotherapy target and dose design guidelines:Expert consensus[J]. Chin J Radiat Oncol, 2011, 20(4):267-269. DOI:10.3760/cma.j.issn.1004-4221.2011.04.001 [21] Wang TJC, Riaz N, Cheng SK, et al. Intensity-modulated radiation therapy for nasopharyngeal carcinoma:a review[J]. J Radiat Oncol, 2012, 1(2):129-146. DOI:10.1007/s13566-012-0020-4. [22] Su SF, Han F, Zhao C, et al. Long-term outcomes of early-stage nasopharyngeal carcinoma patients treated with intensity-modulated radiotherapy alone[J]. Int J Radiat Oncol Biol Phys, 2012, 82(1):327-333. DOI:10.1016/j.ijrobp.2010.09.011. [23] Sun X, Su S, Chen C, et al. Long-term outcomes of intensity-modulated radiotherapy for 868 patients with nasopharyngeal carcinoma:an analysis of survival and treatment toxicities[J]. Radiother Oncol, 2014, 110(3):398-403. DOI:10.1016/j.radonc.2013.10.020. [24] Ou X, Zhou X, Shi Q, et al. Treatment outcomes and late toxicities of 869 patients with nasopharyngeal carcinoma treated with definitive intensity modulated radiation therapy:new insight into the value of total dose of cisplatin and radiation boost[J]. Oncotarget, 2015, 6(35):38381-38397. DOI:10.18632/oncotarget.5420. [25] Zheng Y, Han F, Xiao W, et al. Analysis of late toxicity in nasopharyngeal carcinoma patients treated with intensity modulated radiation therapy[J]. Radiat Oncol, 2015, 10:17. DOI:10.1186/s13014-014-0326-z. [26] Li Y, Ou X, Shen C, et al. Patterns of local failures and suggestions for reduction of clinical target volume for nasopharyngeal carcinoma patients without cervical lymph node metastasis[J]. Onco Targets Ther, 2018, 11:2545-2555. DOI:10.2147/OTT.S158126. [27] Sanford NN, Lau J, Lam MB, et al. Individualization of clinical target volume delineation based on stepwise spread of nasopharyngeal carcinoma:outcome of more than a decade of clinical experience[J]. Int J Radiat Oncol Biol Phys, 2019, 103(3):654-668. DOI:10.1016/j.ijrobp.2018.10.006. [28] Cao C, Jiang F, Jin Q, et al. Locoregional extension and patterns of failure for nasopharyngeal carcinoma with intracranial extension[J]. Oral Oncol, 2018, 79:27-32. DOI:10.1016/j.oraloncology.2018.02.004. [29] Yang H, Chen X, Lin S, et al. Treatment outcomes after reduction of the target volume of intensity-modulated radiotherapy following induction chemotherapy in patients with locoregionally advanced nasopharyngeal carcinoma:A prospective, multi-center, randomized clinical trial[J]. Radiother Oncol, 2018, 126(1):37-42. DOI:10.1016/j.radonc.2017.07.020. [30] Yang X, Ren H, Yu W, et al. Analysis of clinical target volume delineation in local-regional failure of nasopharyngeal carcinoma after intensity-modulated radiotherapy[J]. J Cancer, 2020, 11(7):1968-1975. DOI:10.7150/jca.39588. [31] Guo Q, Zheng Y, Lin J, et al. Modified reduced-volume intensity-modulated radiation therapy in non-metastatic nasopharyngeal carcinoma:A prospective observation series[J]. Radiother Oncol, 2021, 156:251-257. DOI:10.1016/j.radonc.2020.12.035. [32] Liang SB, Sun Y, Liu LZ, et al. Extension of local disease in nasopharyngeal carcinoma detected by magnetic resonance imaging:improvement of clinical target volume delineation[J]. Int J Radiat Oncol Biol Phys, 2009, 75(3):742-750. DOI:10.1016/j.ijrobp.2008.11.053. [33] Li WF, Sun Y, Chen M, et al. Locoregional extension patterns of nasopharyngeal carcinoma and suggestions for clinical target volume delineation[J]. Chin J Cancer, 2012, 31(12):579-587. DOI:10.5732/cjc.012.10095. [34] Lin L, Yao JJ, Zhou GQ, et al. The efficacy and toxicity of individualized intensity-modulated radiotherapy based on the tumor extension patterns of nasopharyngeal carcinoma[J]. Oncotarget, 2016, 7(15):20680-20690. DOI:10.18632/oncotarget.8004. [35] Miao J, Di M, Chen B, et al. A prospective 10-year observationalstudy of reduction of radiation therapy clinical target volume and dose in early-stage nasopharyngeal carcinoma[J]. Int J Radiat Oncol Biol Phys, 2020, 107(4):672-682. DOI:10.1016/j.ijrobp.2020.03.029. [36] Zang J, Li C, Zhao LN, et al. Prognostic model of death and distant metastasis for nasopharyngeal carcinoma patients receiving 3DCRT/IMRT in nonendemic area of china[J]. Medicine (Baltimore), 2016, 95(21):e3794. DOI:10.1097/MD.0000000000003794. [37] Wang HY, Chang YL, To KF, et al. A new prognostic histopathologic classification of nasopharyngeal carcinoma[J]. Chin J Cancer, 2016, 35:41. DOI:10.1186/s40880-016-0103-5. [38] Lin L, Dou Q, Jin YM, et al. Deep learning for automated contouring of primary tumor volumes by MRI for nasopharyngeal carcinoma[J]. Radiology, 2019, 291(3):677-686. DOI:10.1148/radiol.2019182012. [39] Xue X, Qin N, Hao X, et al. Sequential and iterative auto-segmentation of high-risk clinical target volume for radiotherapy of nasopharyngeal carcinoma in planning CT images[J]. Front Oncol, 2020, 10:1134. DOI:10.3389/fonc.2020.01134.
2022, Vol. 31 
